» Articles » PMID: 36719337

Pharmacologic Treatment of Depression in Alzheimer's Disease

Overview
Specialty Pharmacology
Date 2023 Jan 31
PMID 36719337
Authors
Affiliations
Soon will be listed here.
Abstract

Major depressive disorder and Alzheimer's disease are common among older people, frequently co-occur and severely impact the quality of life. Unfortunately, data on the efficacy of pharmacologic treatment of depressive symptoms in patients with the neurodegenerative disease remain inconclusive. The heterogeneity of treatment study designs, from varying diagnostic specificity to diverse outcome measures, contributes to conflicting evidence across single trials and meta-analyses. In this literature review, we focus on commercially available products for antidepressant treatment in demented individuals and show how insights from randomized controlled trials could still guide and be aligned with common clinical practice.

Citing Articles

What do we know about pseudodementia?.

Mouta S, Fonseca Vaz I, Pires M, Ramos S, Figueiredo D Gen Psychiatr. 2023; 36(4):e100939.

PMID: 37622032 PMC: 10445398. DOI: 10.1136/gpsych-2022-100939.


Imbalance of multiple neurotransmitter pathways leading to depression-like behavior and cognitive dysfunction in the triple transgenic mouse model of Alzheimer disease.

Zhang M, Liu L, Xu Y, Wang W, Qiu N, Zhang F Metab Brain Dis. 2023; 38(7):2465-2476.

PMID: 37256468 DOI: 10.1007/s11011-023-01242-2.